Opioid misuse and specifically opioid use disorder (OUD), continues to represent a significant U.S. public health threat, with more than 6 million Americans aged 12 and older meeting the criteria for OUD in 2022. Efforts to ease the crisis have included the development of genetic testing to identify individuals most at risk for OUD. New research questions the usefulness of 15 genetic variants from an algorithm meant to predict OUD risk that was recently granted pre-marketing approval by the Food and Drug Administration. It found that the testing could lead to both false positive and false negative results.